The development of a vitamin A-functionalized self-nanoemulsifying drug delivery system represents a significant advancement in targeting hepatic stellate cells for liver fibrosis treatment. This innovation could enhance treatment efficacy and provide a competitive edge in the hepatology market, necessitating further exploration by pharma companies. Regulatory context from MHRA (ACE-inhibitors: Be aware of the distinction between bradykinin- and histamine-mediated angioedema, as treatment strategies differ significantly) supports the near-term read.